Loren Data's SAM Daily™

FBO DAILY ISSUE OF SEPTEMBER 06, 2003 FBO #0648
SOLICITATION NOTICE

B -- Breakpoint Cloning

Notice Date

9/4/2003
 

Notice Type

Solicitation Notice
 

Contracting Office

Department of Health and Human Services, National Institutes of Health, National Cancer Institute, Research Contracts Br., 6120 Executive Blvd. EPS Suite 600, Rockville, MD, 20852
 

ZIP Code

20852
 

Solicitation Number

NCI-30143-NG
 

Response Due

9/19/2003
 

Archive Date

10/4/2003
 

Point of Contact

Malinda Holdcraft, Purchasing Agent, Phone (301) 402-4509, Fax (301) 402-4513, - Renita Smith, Contract Specialist, Phone 301-496-8612, Fax 301-480-0241,
 

E-Mail Address

holdcram@exchange.nih.gov, rs442i@nih.gov
 

Description

The National Cancer Institute (NCI), Center for Clinical Research, Genetics Branch intends on entering into an agreement with Lynx Therapeutics, Inc., 25861 Industrial Blvd., Hayward, California, 94545. The services and supplies herein are being procured using the simplified acquisition procedures as stated in FAR Part 13. The North American Industrial Classification System code is 541990 and the business size standard is $6M. The purpose of this project is for work supporting extramural and private initiatives for structural characterization of cancers and derived cancer cell lines using "massively parallel signature" sequencing technology. The goal of this work is to; 1) build a foundation of datasets representing the elucidation of the genome anatomy for selected tumors, cell lines, and cell lineages, 2) integrate these datasets with data on gene expression, morphology, virulence, and other phenotypic parameters and; 3) use the foundation of this work for the formulation of testable hypotheses concerning required steps in the development and progression of cancer, lineage specific mechanisms of instability, genotype-phenotype relationships, and the basis of evolutionary selection or programmatic choice. We will furthermore sequence relevant breakpoints through the use of long-range PCR with reference to the completed sequence of the human genome. The screening process for sequences of interest is to develop four categories of clones: a) those whose ends are consistent with contiguity of the human genome sequence, b) those whose two ends appear to be discontinuous compared to the human genome sequence and for which we have more than one independent example where the two novel genomic regions are juxtaposed, c) those where we have only one example of a novel juxtaposition but we have additional molecular cytogenetic data to support this novel juxtaposition and; d) those for which we have only one example of a novel juxtaposition (this category would be addressed as the lowest priority). Lynx Therapeutics, Inc., is the only source known to the National Cancer Institute of their patented technology that offers the sequence coverage necessary for this comprehensive analysis. Lynx Megaclone Technology is a proprietary technology that captures simultaneously on millions of micro-beads, the DNA "signature ditag," molecules in a sample from a complex mixture of DNA, (e.g. cDNA, genomic fragments, etc.). Each molecule is cloned on a five-micron plastic bead. Approximately 100,000 copies of each "signature ditag" molecule in the original sample are randomly distributed over the surface of one bead for MPSS "signature tag" sequencing. Proprietary Lynx Combi-Tags are used for "signature tag" capture. This is not a request for competitive quotation. However, if any interested party believes it can meet the above requirements unique features, it may submit a statement of capabilities. The statement of capabilities and any other information furnished must be in writing and must contain material in sufficient detail to allow NCI research to determine if the party can perform this requirement. An original and one (1) copy of the capability statement must be received in the contracting office by 1:00 PM EST on September 19, 2003. All questions must be in writing and can be faxed to (301) 402-4513 or emailed to holdcram@exchange.nih.gov. A determination by the Government not to compete this proposed requirement based upon responses t this notice is solely within the discretion of the Government. Information received will be considered solely for the purpose of determining whether to conduct a competitive procurement. No collect calls will be accepted.
 

Place of Performance

Address: NCI/NIH

Zip Code: 20892

Country: USA
 

Record

SN00425043-W 20030906/030904213138 (fbodaily.com)
 

Source

FedBizOpps.gov Link to This Notice
(may not be valid after Archive Date)

---

| FSG Index  |  This Issue's Index  |  Today's FBO Daily Index Page |